Paul Bolno, Wave Life Sciences CEO
June 25, 2024 11:27 AM EDT
R&D

Wave Life Sci­ences touts Hunt­ing­ton's dis­ease win in Phase 1b/2a tri­al

Max Gelman

Senior Editor

Wave Life Sci­ences said Tues­day that its ex­per­i­men­tal Hunt­ing­ton’s dis­ease ther­a­py ef­fec­tive­ly low­ered the mu­tant hunt­ingtin pro­tein (mHTT) lev­els as­so­ci­at­ed with the dis­ease in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times